182 related articles for article (PubMed ID: 21457408)
1. The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one-stage clotting assay.
Pouplard C; Caron C; Aillaud MF; Ternisien C; Desconclois C; Dubanchet A; Sobas F
Haemophilia; 2011 Sep; 17(5):e958-62. PubMed ID: 21457408
[TBL] [Abstract][Full Text] [Related]
2. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII).
Santoro C; Iorio A; Ferrante F; Pallotta A; Pignoloni P; Biondo F; Agnelli G; Mazzucconi MG
Haemophilia; 2009 May; 15(3):779-87. PubMed ID: 19298379
[TBL] [Abstract][Full Text] [Related]
3. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays.
Ingerslev J; Jankowski MA; Weston SB; Charles LA;
J Thromb Haemost; 2004 Apr; 2(4):623-8. PubMed ID: 15102018
[TBL] [Abstract][Full Text] [Related]
4. Measurement of B-domain-deleted ReFacto AF activity with a product-specific standard is affected by choice of reagent and patient-specific factors.
Jacquemin M; Vodolazkaia A; Toelen J; Schoeters J; Van Horenbeeck I; Vanlinthout I; Debasse M; Peerlinck K
Haemophilia; 2018 Jul; 24(4):675-682. PubMed ID: 28124445
[TBL] [Abstract][Full Text] [Related]
5. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII.
Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TA; Walker ID
Haemophilia; 2016 Sep; 22(5):806-12. PubMed ID: 27217329
[TBL] [Abstract][Full Text] [Related]
6. A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards.
Morfini M; Cinotti S; Bellatreccia A; Paladino E; Gringeri A; Mannucci PM;
J Thromb Haemost; 2003 Nov; 1(11):2283-9. PubMed ID: 14629459
[TBL] [Abstract][Full Text] [Related]
7. Factor VIII recovery after a single infusion of recalibrated ReFacto in 14 severe haemophilia A patients.
Lambert T; Guérois C; Gay V; Stieltjes N; Bertrand MA; Derlon A; Sigaud M; Hassoun A; Négrier C; Coatmelec B; Dreyfus M; Dubanchet A
Haemophilia; 2007 Jul; 13(4):357-60. PubMed ID: 17610548
[TBL] [Abstract][Full Text] [Related]
8. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
[TBL] [Abstract][Full Text] [Related]
9. Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent.
Mazurier C; Parquet-Gernez A; Goudemand M
Thromb Haemost; 1990 Oct; 64(2):251-5. PubMed ID: 2125374
[TBL] [Abstract][Full Text] [Related]
10. A blinded in vitro study with Refacto mock plasma samples: similar FVIII results between the chromogenic assay and a one-stage assay when using a higher cephalin dilution.
Caron C; Dautzenberg MD; Delahousse B; Droulle C; Pouzol P; Dubanchet A; Rothschild C
Haemophilia; 2002 Sep; 8(5):639-43. PubMed ID: 12199672
[TBL] [Abstract][Full Text] [Related]
11. Practical and cost-effective measurement of B-domain deleted and full-length recombinant FVIII in the routine haemostasis laboratory.
Cauchie M; Toelen J; Peerlinck K; Jacquemin M
Haemophilia; 2013 May; 19(3):e133-8. PubMed ID: 23374099
[TBL] [Abstract][Full Text] [Related]
12. International comparative field study of N8 evaluating factor VIII assay performance.
Viuff D; Barrowcliffe T; Saugstrup T; Ezban M; Lillicrap D
Haemophilia; 2011 Jul; 17(4):695-702. PubMed ID: 21426445
[TBL] [Abstract][Full Text] [Related]
13. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.
Barrowcliffe TW; Raut S; Sands D; Hubbard AR
Semin Thromb Hemost; 2002 Jun; 28(3):247-56. PubMed ID: 12098084
[TBL] [Abstract][Full Text] [Related]
14. A multi-centre collaborative study on the potency estimation of ReFacto.
Hubbard AR; Sands D; Sandberg E; Seitz R; Barrowcliffe TW
Thromb Haemost; 2003 Dec; 90(6):1088-93. PubMed ID: 14652641
[TBL] [Abstract][Full Text] [Related]
15. [Factor VIII assays in treated hemophilia A patients].
Lasne D; Pouplard C; Nougier C; Eschwege V; Le Cam Duchez V; Proulle V; Smahi M; Harzallah I; Voisin S; Toulon P; Sobas F; Galinat H; Flaujac C; Ternisien C; Jeanpierre E;
Ann Biol Clin (Paris); 2019 Feb; 77(1):53-65. PubMed ID: 30799298
[TBL] [Abstract][Full Text] [Related]
16. Predictive immunogenicity of Refacto AF.
Delignat S; Repessé Y; Gilardin L; Dimitrov JD; Lone YC; Kaveri SV; Lacroix-Desmazes S
Haemophilia; 2014 Jul; 20(4):486-92. PubMed ID: 24372710
[TBL] [Abstract][Full Text] [Related]
17. ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A.
Di Paola J; Smith MP; Klamroth R; Mannucci PM; Kollmer C; Feingold J; Kessler C; Pollmann H; Morfini M; Udata C; Rothschild C; Hermans C; Janco R
Haemophilia; 2007 Mar; 13(2):124-30. PubMed ID: 17286764
[TBL] [Abstract][Full Text] [Related]
18. A collaborative study to establish a Korean Standard for factor VIII:C concentrate.
Kang HN; Kim SN; Lee SH; Hong SH
Thromb Res; 2004; 113(3-4):261-7. PubMed ID: 15140591
[TBL] [Abstract][Full Text] [Related]
19. Analytical variation in factor VIII one-stage and chromogenic assays: Experiences from the ECAT external quality assessment programme.
van Moort I; Meijer P; Priem-Visser D; van Gammeren AJ; Péquériaux NCV; Leebeek FWG; Cnossen MH; de Maat MPM
Haemophilia; 2019 Jan; 25(1):162-169. PubMed ID: 30488994
[TBL] [Abstract][Full Text] [Related]
20. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C).
Shima M; Matsumoto T; Fukuda K; Kubota Y; Tanaka I; Nishiya K; Giles AR; Yoshioka A
Thromb Haemost; 2002 Mar; 87(3):436-41. PubMed ID: 11916076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
